New Analysis Finds More than Half of Brand Medicine Spending Goes to the Supply Chain, Middlemen and Other Stakeholders
BRG is home to renowned thought leaders and experts considered authorities in their fields of work. Our timely research and perspectives provide analysis and insights on the most important issues facing the industries and organizations we serve.
More than half (50.5%) of every $1 spent on brand medicines went to payers, middlemen, providers and other stakeholders in 2020, according to a new analysis from Berkeley Research Group (BRG), “The Pharmaceutical Supply Chain, 2013–2020.” For the first time since BRG began tracking trends in pharmaceutical spending eight years ago, the share of brand medicine spending retained by biopharmaceutical companies has fallen to less than half (49.5%) as rebates, discounts and other payments to the supply chain and other stakeholders steadily increased.
The report, which builds on previous BRG studies, analyzes payments made by patients and their health plans at the pharmacy counter or paid on a claim to a healthcare provider.
Related Professionals
Prepare for what's next.
ThinkSet magazine, a BRG publication, provides nuanced, multifaceted thinking and expert guidance that help today’s business leaders adopt a more strategic, long-term mindset to prepare for what’s next.